The FDA to meet on evaluation of opioid drug products with abuse-deterrent properties
Health outlook for week of November 14
How the FDA Priority Review Voucher Program Works
FDA NME and BLA approvals decreased drastically in 2016
Health outlook: post AHCA failure, Congress returns to other health agenda items
Health outlook for the week of April 24
Trump’s FDA nominee Scott Gottleib has close ties to pharmaceutical industry
This content is a benefit not included in your current membership package.
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.